Table 3 Variables significantly associated with time to therapy (TTT) in univariate and multivariate analyses
Baseline data | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Â | Relative ratio (95% CI) | p-value | Relative ratio (95% CI) | p-value |
Age at referrala | 1.03 (0.99–1.07) | 0.14 |  |  |
Ethnicity | ||||
 Asian or Pakistani | 1 | 0.007 | 1 | 0.01 |
 White British | 1.18 (1.04–1.34) |  | 1.13 (1.00–1.28) |  |
 Other ethnic group | 1.40 (1.08–1.81) |  | 1.41 (1.10–1.80) |  |
IBD type | ||||
 UC ( +) | 1 | 0.02 | 1 | 0.02 |
 CD | 1.16 (1.03–1.32) |  | 1.18 (1.03–1.34) |  |
Completed funding application | ||||
 Yes | 1 | 0.07 | 1 | 0.06 |
 No | 1.15 (0.99–1.34) |  | 1.15 (1.00–1.33) |  |
Biologic drug | ||||
 Infliximab | 1 | 0.008 | 1 | 0.001 |
 Adalimumab | 1.24 (105–1.46) |  | 1.25 (1.06–1.46) |  |
 Vedolizumab | 1.02 (0.87–1.18) |  | 1.00 (0.86–1.19) |  |
 Ustekinumab | 0.91 (0.75–1.10) |  | 0.86 (0.71–1.04) |  |